ANI Pharmaceuticals Inc 2024年度报告

FORM10-K xANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedDecember31, 2024 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______.Commission file number001-31812ANI PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter) Name of each exchange on which registered Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesoNox Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesoNox Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.(Check one): If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financialreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.x If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statementso Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesoNox The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of June 28, 2024 was$1.2billion(based upon the lastreported sale price of$63.68per share on June 30, 2024, on The Nasdaq Global Market). As ofFebruary21, 2025,21,762,646sharesof common stock and10,864shares of Class C Special stock of the registrant were outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement for the registrant’s 2025 annual meeting of stockholders to be filed within 120 days after the end of the period covered by thisAnnual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K. ANI PHARMACEUTICALS, INC.ANNUAL REPORT ON FORM 10-KFor the Year Ended December 31, 2024TABLE OF CONTENTS PART I Item 1.Item 1A.Item 1B.Item 1C.Item 2.Item 3.Item 4. BusinessRisk FactorsUnresolved Staff CommentsCybersecurityPropertiesLegal ProceedingsMine Safety Disclosures PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities61Item 6.Reserved63Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations64Item 7A.Quantitative and Qualitative Disclosures About Market Risk86Item 8.Financial Statements and Supplementary Data87Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure151Item 9A.Controls and Procedures151Item 9B.Other Information152Item 9C.Disclosures Regarding Foreign Jurisdictions that Prevent Inspections152 PART III Item 10.Directors, Executive Officers and Corporate Governance152Item 11.Executive Compensation153Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters153Item 13.Certain Relationships and Related Transactions, and Director Independence153Item 14.Principal Accountant Fees and Services153 PART IV Item 15.Exhibits and Financial Statement Schedules153Item 16.Form 10-K Summary160 Signatures161 In this annual report, references to “ANI Pharmaceuticals